These primarily inhibit the formation of osteoclasts from pre-osteoclasts. Denosumab is currently in phase 3 testing, and there is a separate page for these drugs.
These primarily inhibit the formation of osteoclasts from pre-osteoclasts. Denosumab is currently in phase 3 testing, and there is a separate page for these drugs.
Boyce BF. Regulation of bone remodeling and emerging breakthrough drugs for osteoporosis and osteolytic bone metastases. Kidney Int Suppl 2003(85):S2-5.
Fratzl-Zelman N. Decreased bone turnover and deterioration of bone structure in two cases of pycnodysostosis. J Clin Endocrinol Metab 2004;89(4):1538-47.
Horton MA. Upregulation of osteoclast alpha2beta1 integrin compensates for lack of alphavbeta3 vitronectin receptor in Iraqi-Jewish-type Glanzmann thrombasthenia. Br J Haematol 2003;122(6):950-7.
Krishnan V. Regulation of bone mass by Wnt signaling. J Clin Invest 2006;116(5):1202-9.
McClung MR. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006;354(8):821-31.
McHugh KP. Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts. J Clin Invest 2000;105(4):433-40.
Murphy MG. Effect of L-000845704, an alphaVbeta3 integrin antagonist, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Clin Endocrinol Metab 2005;90(4):2022-8.
Yarali N. Osteopetrosis and Glanzmann's thrombasthenia in a child. Ann Hematol 2003;82(4):254-6.
Updated 5/11/06
